PEComa Epidemiology Forecast 2025-2034

Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors that can be both benign and malignant. PEComa-NOS, angiomyolipoma, and lymphangioleiomyomatosis are all members of the PEComa tumor family. They are typically intermittent. The PEComa epidemiology forecast suggests that it has an estimated frequency of 0.3 per 1,000,000.

PEComa Epidemiology Forecast Report Coverage

The “PEComa Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of PEComa. It projects the future incidence and prevalence rates of PEComa across various populations. The study covers age, gender, and type as major determinants of the PEComa-affected population. The report highlights patterns in the prevalence of PEComa over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of PEComa in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

PEComa Understanding: Disease Overview

PEComa is an uncommon kind of mesenchymal tumor that is distinguished by the presence of perivascular epithelioid cells. The uterus, lungs, kidneys, and soft tissues are among the organs where these tumors might develop. TSC1 or TSC2 gene mutations, which are connected to the tuberous sclerosis complex, are frequently linked to PEComas. Some cases can be aggressive and spread, although the majority are benign. Histopathology and immunohistochemical markers such as HMB-45 and Melan-A are commonly used to confirm the diagnosis.

PEComa Epidemiology Perspective

The PEComa epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for PEComa by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for PEComa and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to a study, in clinical practice, malignant PEComa of the colon might be mistaken for malignant melanoma, gastrointestinal stromal tumor, or adenoma. Approximately 54% of women and 46% of men experienced gastrointestinal tract metastases of PEComas in the study.
• A study indicated that poor prognosis is linked to advanced malignant PEComa. Most patients are female, and they are usually diagnosed between the ages of 45 and 65.
• Research shows that between 12 and 23 months after their initial diagnosis, 51% to 72% of patients with malignant PEComas develop disease metastases. The prognosis is significantly impacted by metastasis, which most frequently occurs in the lungs, liver, and lymph nodes. To control the course of the disease and enhance patient outcomes, early detection and careful observation are essential.
• A study conducted in United Sates revealed that the lifetime risk of heart failure has risen to 24%, meaning that roughly 1 in 4 individuals will develop the condition during their lifetime.

Country-wise PEComa Epidemiology

The PEComa epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of PEComa varies between countries owing to the differences in factors such as certain genetic and biological factors natural environmental factors, and others. According to some studies, an estimated 100-300 new patients are diagnosed with malignant PEComa each year in the United States and around 0.3 out of a total of 1,000,000 people worldwide.

PEComa: Treatment Overview

The size, location, and propensity for aggressiveness of the tumor decides the treatment option. The main strategy for localized tumors is surgical resection, which aims for total removal with distinct margins. Because of their association with TSC1/TSC2 mutations, targeted therapy such mTOR inhibitors (e.g., sirolimus, everolimus) are frequently employed for advanced or metastatic patients. Chemotherapy and radiation are occasionally considered, especially for severe or incurable cancers. Monitoring progression or recurrence requires routine follow-up.

Key Questions Answered

• What are the key findings of PEComa epidemiology in the 8 major markets?
• What will be the total number of patients with PEComa across the 8 major markets during the forecast period?
• What was the country-wise prevalence of PEComa in the 8 major markets in the historical period?
• Which country will have the highest number of PEComa patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of PEComa during the forecast period of 2025-2034?
• What are the currently available treatments for PEComa?
• What are the disease risks, signs, symptoms, and unmet needs of PEComa?

This product will be delivered within 3-5 business days.